Sign in
CompletedNo phase

Attexis and tDCS for the Treatment of ADHD

Key facts

Who runs it
University of Regensburg
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
30 people enrolled
Started
1 Sept 2024
Ended
24 Feb 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • transcranial direct current stimulation
  • sham transcranial direct current stimulation
Record updated
27 February 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Gender: female, male, non-binary
  • Age: 18 - 65
  • Diagnosis of ADHD according to ICD-10
  • ADHD severity score (cut-off): Score of ≥17 on either the inattention subscale or the impulsivity/hyperactivity subscale of the ASRS v1.1
  • Stable treatment (psychotherapy, medication, no treatment, ...) (if applicable) for at least 30 days at the time of admission
  • Consent to participate
  • Sufficient knowledge of the German language

Who cannot take part

  • Plan to change an ongoing treatment (psychotherapy, medication, ...) in the next three months after enrollment in the study
  • Fulfillment of the contraindications for tDCS (electrical implants or metallic objects in the body such as pacemakers or insulin pumps, skin diseases on the head)
  • Neurological diseases (e.g. cerebrovascular events, neurodegenerative diseases, epilepsy, brain malformation, history of severe head injuries)
  • Diagnosis of a comorbid clinically relevant severe psychiatric disorder (severe affective disorder, autism spectrum disorder, psychotic disorder, borderline personality disorder, antisocial personality disorder, substance use disorder, suicidality)
  • tDCS:
  • Participation in another study during treatment
  • Pregnancy or breastfeeding; Attexis:

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A randomized controlled two-arm study (RCT) will be conducted. It is planned to randomly assign eligible patients who receive a three-month access to the psychotherapeutic program (Attexis) to either an additional verum-tDCS or placebo-tDCS condition.

The 2 groups in the trial

  • Attexis and tDCSTreatment being tested

    15 patients receive three-month access to the psychotherapy app attexis and a tDCS device from the company Sooma, which is set to verum

    Treatment: transcranial direct current stimulation

  • Attexis and placebo-tDCSPlacebo, for comparison

    15 patients receive three-month access to the psychotherapy app attexis and a tDCS device from the company Sooma, which is set to sham

    Treatment: sham transcranial direct current stimulation

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Augmentation Von Online-Psychotherapie Mit tDCS Bei Der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS)
Record updated
27 February 2026